RT Journal Article
SR Electronic
T1 Nuclear Matrix Protein 22 for Bladder Cancer Detection: Comparative Analysis of the BladderChek® and ELISA
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5093
OP 5097
VO 32
IS 11
A1 GEORGIOS HATZICHRISTODOULOU
A1 HUBERT KÜBLER
A1 HARTWIG SCHWAIBOLD
A1 STEFAN WAGENPFEIL
A1 CORNELIA EIBAUER
A1 CHRISTIAN HOFER
A1 JÜRGEN GSCHWEND
A1 UWE TREIBER
YR 2012
UL http://ar.iiarjournals.org/content/32/11/5093.abstract
AB Aim: To compare nuclear matrix protein 22 expression by BladderChek® and ELISA, as urine-based assays for bladder cancer (BC) detection. Patients and Methods: Urine samples of 100 BC patients and 100 controls were analyzed. Comparative statistical evaluations were based on sensitivity and specificity. Results: Seventy-one patients had primary and 29 recurrent BC. The sensitivity of BladderChek® was significantly higher compared to ELISA in the overall cancer cohort and in patients with primary BC (p<0.0001 and p=0.0001, respectively). Both tests demonstrated significant correlation of sensitivities and tumor stage/grade for the overall cancer cohort and for patients with primary BC. Both tests had specificity values of 100% in healthy individuals. Specificity was 93% for BladderChek® and 99% for ELISA in patients with benign diseases (p=0.048). Conclusion: BladderChek® may be clinically more useful for BC detection. Due to high specificity, BladderChek® could be used for high-risk screening. However, due to its low sensitivity, BladderChek® cannot replace but only complement cystoscopy for BC detection.